Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours.

MicroRNAs are aberrantly expressed in many cancers and can exert tumor suppressive or oncogenic functions. Since oncomirs promote growth of cancer cells and support survival during chemotherapy, thus microRNA silencing therapies could be a valuable approach to be associated with anticancer drugs and chemotherapy treatments. miR-155 microRNA was found overexpressed in different types of cancer, such as leukemias (PML, B-cell lymphomas), lung cancer and glioblastoma. GABA-A receptor downregulation was found correlated with glioma grading, with decreasing levels associated to higher grade of malignancies. A relationship between knock down of miR-155 and re-expression of GABRA 1 protein in vivo was recently individuated. This finding has implication on the effectiveness of RNA silencing approaches against miR-155 with the scope to control proliferation and signalling pathways regulated by GABA-A Receptor. Applying microRNAs for treatment of brain tumours poses several problems, and fields to be solved are mainly the passage of the brain-blood-barrier (BBB) and the targeted delivery to specific cell types. GBM cells bud off microvesicles that deliver cytoplasmic contents to nearby cells. Thus, the exploitation of these mechanisms to deliver antagomir therapeutics targeting microvescicles in the brain could take the lead in the near future in the treatment of brain cancers in substitution of invasive surgical intervention.